HighTide Therapeutics, Inc. (HKG:2511)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.030
+0.380 (14.34%)
At close: Mar 10, 2026
200.00%
Market Cap 1.51B
Revenue (ttm) n/a
Net Income (ttm) -319.05M
Shares Out 571.33M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,144,000
Average Volume 1,133,613
Open 2.700
Previous Close 2.650
Day's Range 2.700 - 3.160
52-Week Range 0.990 - 4.700
Beta 0.29
RSI 65.35
Earnings Date Mar 27, 2026

About HighTide Therapeutics

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 57
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2511
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.